More on AMRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $20.48 |
|
|||
| Open | $20.45 | ||||
| 52 Wk High | $0.19 | ||||
| 52 Wk Low | $0.07 | ||||
| Day High | $20.49 | ||||
| Day Low | $19.93 | ||||
| P/E | N/A | ||||
| EPS | $-0.01 | ||||
| Volume | 4,925,129 | ||||
- Form 8-K/A Amneal Pharmaceuticals, For: Aug 10
- Amneal Pharmaceuticals (AMRX) PT Raised to $24 at JPMorgan
- Amneal to Report Third Quarter 2026 Results on November 3, 2026
- UBS Reiterates Buy Rating on Amneal Pharmaceuticals (AMRX)
- Oppenheimer Starts Amneal Pharmaceuticals (AMRX) at Outperform
- Form 4 Amneal Pharmaceuticals, For: Sep 11 Filed by: BUCHI J KEVIN
- Form 4 Amneal Pharmaceuticals, For: Sep 17 Filed by: BUCHI J KEVIN
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Amneal Pharmaceuticals (AMRX) PT Raised to $20 at Barclays
Entities mentioned with AMRX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13D | View Related Stories »
- 13G | View Related Stories »
- Show More...
